DB07107

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

DB07107 

DB07107 是一种有效的抗药性 T315I 突变 Bcr-Abl (T315I mutant Bcr-Abl) 酪氨酸激酶抑制剂。DB07107 还是一种有效的 Akt1 抑制剂，IC50 值为 360 nM。

DB07107

DB07107 Chemical Structure

CAS No. : 552332-71-5

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

DB07107 is a potent drug resistant T315I mutant Bcr-Abl tyrosine kinase inhibitor. DB07107 is also a potent Akt1 inhibitor with an IC50 value of 360 nM[1][2].

IC50 & Target[1][2]

Akt1

360 nM (IC50)

体外研究
(In Vitro)

DB07107 is more effective in blocking drug-resistant T315I mutant than the wild-type Bcr-Abl. DB07107 (C23H22N4O) from DrugBank showed the highest binding energy with XP score of -14.045 kcal/mol[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

370.45

Formula

C23H22N4O
CAS 号

552332-71-5
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Banavath HN, et al. Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study. Sci Rep. 2014 Nov 10;4:6948.

    [2]. Li Q, et al. Discovery of trans-3,4′-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1679-85.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务